Skip to main content

Table 1 Baseline Clinical characteristics

From: Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation

Characteristics

Ezetimibe /simvastatin (n = 25)

Rosuvastatin (n = 25)

p-value

Age, years

62.5 ± 7.4

59.2 ± 8.8

0.154

Men

22 (88.0%)

21 (84.0%)

0.684

Current smoker

4 (16.0%)

5 (20.0%)

0.713

Diabetes mellitus

2 (8.0%)

3 (12.0%)

0.637

Hypertension

17 (68.0%)

10 (40.0%)

0.047

Diagnosis

  

0.301

 STEMI

19 (76.0%)

19 (76.0%)

 

 NSTE-ACS

6 (2.0%)

6 (24.0%)

 

Culprit artery of ACS

  

0.345

 Left anterior descending coronary

17 (68.0%)

16 (64.0%)

 

 Left circumflex coronary

2 (8.0%)

0 (0%)

 

 Right coronary

6 (24.0%)

8 (32.0%)

 

 Ramus intermedius

0 (0%)

1 (4.0%)

 

Culprit lesion PCI

24 (97.5%)

25 (100%)

0.848

Left ventricular ejection fraction (%)

52.9 ± 8.2

53.9 ± 73

0.718

Medications at the time of follow-up

 Aspirin

25 (100%)

25 (100%)

1.0

 P2Y12 inhibitors

25 (100.0%)

25 (100.0%)

1.0

 β-blockers

22 (88.0%)

19 (76.0%)

0.269

 Angiotensin II receptor blocker

12 (48.0%)

13 (52.0%)

0.777

 Calcium channel blocker

13 (52.0%)

12 (48.0%)

0.777

  1. CAD Coronary artery disease, STEMI ST-Segment elevation myocardial infarction, NSTE-ACS Non-ST-segment elevation-acute coronary syndrome, PCI Percutaneous coronary intervention